A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Financial Summary
| Share Statistics | LZAGY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $48,574.8 | $1,790.4 | 93% |
|
| Shares Out (Mil) | 86.6 | 94.8 | 59% |
|
| Institutional Ownership | 49.9% | 90.0% | 27% |
|
| Float (Mil) | 69.8 | 69.9 | 55% |
|
| Beta | 0.85 | 1.20 | 50% |
|
| Avg Daily Volume (000s) | 57 | 814 | 30% |
|
| Price Change (52-week) |
(1.2%) | 80.2% | 44% |
|
| Growth | LZAGY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.1% | 7.8% | 58% |
|
| Net Income (5yr) | (18.7%) | (13.7%) | 21% |
|
| EPS (5yr) | (18.9%) | 0.7% | 14 |
|
| Dividends (5yr) | 13.2% | 0.0% | 98% |
|
| Cash Flow (5yr) | (38.2%) | (15.0%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LZAGY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8,504 | $785 | 82% |
|
| Net Income (TTM) (Mil) | ($136) | ($14) | 9% |
|
| EPS (TTM) | ($1.948) | ($0.200) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | $1,776 | $53 | 87% |
|
| Net Cash Flow (TTM) (Mil) | na | ($4) | na |
|
| Long-Term Debt (Q1) (Mil) | $4,199 | $270 | 84% |
|
| Enterprise Value (Q1) (Mil) | $50,961 | $2,444 | 92% |
|
| Valuation | LZAGY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.92 | na |
|
| P/E | na | 43.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | LZAGY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.1% | 47.6% | 45% |
|
| Net Margin | (1.6%) | (2.9%) | 29% |
|
| ROA | (0.6%) | (2.8%) | 37% |
|
| ROE | (1.3%) | (4.5%) | 34% |
|
| Liabilities to Assets | 55.4% | 43.0% | 48% |
|
| F-Score | na | 5 | na |
|
Lonza Group AG did not pass any screens on 7/31/2026.
